Table II.
Univariate and multivariate Cox proportional hazards models for factors associated with mortality in stage I lung adenocarcinoma patients.
| A, Stage I (n=75) | |||||||
|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | ||||||
| Characteristics | Comparison | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age, years | <65 vs. ≥65 | 0.93 | 0.37–2.30 | 0.87 | 0.96 | 0.33–2.79 | 0.94 |
| Sex | Female vs. male | 0.95 | 0.39–2.34 | 0.91 | 1.94 | 0.60–6.22 | 0.27 |
| Tobacco smoking | No vs. yes | 0.57 | 0.23–1.42 | 0.23 | 0.49 | 0.15–1.56 | 0.23 |
| Grade | G1 vs. G2+G3 | 1.59 | 0.57–4.43 | 0.37 | 1.41 | 0.41–4.83 | 0.59 |
| T stage | T1 vs. T2-T4 | 1.29 | 0.51–3.28 | 0.59 | 1.44 | 0.46–4.53 | 0.53 |
| UFT | No vs. yes | 1.19 | 0.46–3.08 | 0.72 | 1.00 | 0.36–2.81 | 1.00 |
| EGFR expression | EGFR− vs. EGFR+ | 2.98 | 1.21–7.36 | 0.02 | 2.64 | 0.88–7.92 | 0.08 |
| ABCB1 status | ABCB1− vs. ABCB1+ | 3.11 | 1.08–8.97 | 0.04 | 2.53 | 0.76–8.47 | 0.13 |
| B, EGFR wild-type (n=56) | |||||||
| Univariate analysis | Multivariate analysis | ||||||
| Characteristics | Comparison | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age, years | <65 vs. ≥65 | 5.50 | 0.69–43.14 | 0.11 | 4.73 | 0.55–40.71 | 0.16 |
| Sex | Female vs. male | 1.27 | 0.33–4.91 | 0.73 | 1.91 | 0.36–10.16 | 0.45 |
| Tobacco smoking | No vs. yes | 1.56 | 0.33–7.33 | 0.58 | 1.30 | 0.18–9.29 | 0.80 |
| Grade | G1 vs. G2+G3 | 1.27 | 0.33–4.92 | 0.73 | 0.54 | 0.12–2.47 | 0.42 |
| T stage | T1 vs. T2-T4 | 5.86 | 0.74–46.42 | 0.09 | 6.82 | 0.67–69.08 | 0.10 |
| UFT | No vs. yes | 0.57 | 0.15–2.20 | 0.42 | 0.26 | 0.06–1.09 | 0.07 |
| ABCB1 status | ABCB1− vs. ABCB1+ | 3.92 | 0.92–16.78 | 0.07 | 3.58 | 0.70–18.41 | 0.13 |
HR, hazard ratio; CI, confidence interval; EGFR, epidermal growth factor receptor; ABCB1, ATP binding cassette subfamily B member 1; UFT, uracil-tegafur.